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Abstract 
Purpose 
To assess the outcome of prostate cancer (PCa) patients diagnosed with oligometastatic 
disease at recurrence and treated with stereotactic body radiotherapy (SBRT). 
Methods 
Non-castrate patients with up to 3 synchronous metastases (bone and/or lymph nodes) 
diagnosed on positron emission tomography - computed tomography, following biochemical 
recurrence after local curative treatment, were treated with (repeated) SBRT to a dose of 50 
Gy in 10 fractions or 30 Gy in 3 fractions. Androgen deprivation therapy-free survival (ADT-
FS) defined as the time interval between the first day of SBRT and the initiation of ADT was 
the primary endpoint. ADT was initiated if more than 3 metastases were detected during 
follow-up even when patients were still asymptomatic. Secondary endpoints were local 
control, progression free survival (PFS) and toxicity. Toxicity was scored using the Common 
Terminology Criteria for Adverse Events. 
Results 
With a median follow-up from time of SBRT of 2 years, we treated 50 patients with 70 
metastatic lesions with a local control rate of 100%. The primary involved metastatic sites 
were lymph nodes (54%), bone (44%), and viscera (2%). The median PFS was 19 mo (95% 
CI: 13–25 mo) with 75% of recurring patients having ≤3 metastases. A 2nd and 3rd course of 
SBRT was delivered in 19 and 6 patients respectively. This results in a median ADT-FS of 25 
months (20–30 mo). On univariate analysis, only a short PSA doubling time was a significant 
predictor for both PFS (HR: 0.90, 95%CI: 0.82 – 0.99) and ADT-FS (HR: 0.83; 95%CI: 0.71 
– 0.97). Ten patients (20%) developed toxicity following treatment, which was classified as 
grade I in 7 and grade II in 3 patients. 
Conclusion 
Repeated SBRT for oligometastatic prostate cancer postpones palliative androgen deprivation 
therapy with 2 years without grade III toxicity. 
Keywords 
Oligometastases, Prostate cancer, Recurrence, Salvage therapy, Stereotactic body 
radiotherapy 
Background 
The standard treatment options for non-castrated prostate cancer (PCa) patients diagnosed 
with metastatic disease have remained unchanged over the past years [1], with continuous 
androgen deprivation therapy (ADT) being the cornerstone of treatment [2]. The negative 
impact of ADT on general health and quality of life has resulted in a search for alternatives 
[3,4]. Both intermittent ADT and active surveillance are now being considered valuable 
options in these patients [2]. 
Like in other solid tumors, there is increasing evidence that patients diagnosed with a limited 
number of metastases (≤3) – so called “oligometastases” - have a better prognosis compared 
to patients with extensive metastatic disease [5,6]. This might imply that the oligometastatic 
status represents a specific metastatic phenotype with a less aggressive behaviour. The 
clinical implication might be that a localized form of cancer treatment may be effective to 
delay disease progression [7]. Stereotactic body radiotherapy (SBRT) has proven to be a safe 
and effective treatment for oligometastases [8]. 
In the current study we assessed the outcome of PCa patients diagnosed with oligometastatic 
recurrence and treated with SBRT. 
Methods 
This study includes 50 patients diagnosed with ≤ 3 metachronous asymptomatic metastases 
treated with SBRT at our institution between May 2005 and October 2013. Data for these 
patients were prospectively collected and analysed. All cases were presented to and approved 
by the multidisciplinary uro-oncology team and the local ethics committee (EC2011/495). 
Eligibility criteria included histologically proven diagnosis of PCa and a biochemical relapse 
following local radical PCa treatment [9]. Exclusion criteria included: serum testosterone 
level <50 ng/ml at time of detection of metastases, neo-adjuvant or concomitant ADT > 1 
month with SBRT or a PSA rise while on active treatment with a luteinizing hormone 
releasing hormone (LHRH)-(ant)agonist, anti-androgen or estrogens. 
All patients were staged with [18 F]-fluorodeoxyglucose (FDG) (n = 32) until 2011, 
switching to [18 F]-choline positron emitting tomography (PET) until present (n = 18) with 
co-registered computed tomography (CT) [10]. All scans were interpreted by the radiologist 
and nuclear medicine physician in consensus reading with knowledge of the clinical history 
of the patients and of the results of other diagnostic techniques. Every focal tracer 
accumulation deviating from the physiological distribution of the tracer was regarded as 
suggestive of disease. A biopsy of the suspected lesions was not routinely performed prior to 
inclusion and treatment. In case of equivocal findings on PET-CT, an additional magnetic 
resonance imaging (MRI) of the suspected region was performed (n = 11). Local recurrence 
was excluded with digital rectal examination in all cases and with multiparametric MRI in 
patients treated with primary radiotherapy [11,12]. 
SBRT technique 
All patients underwent a CT-based treatment planning with 2–3 mm slice thickness in supine 
position with an ankle and knee fix (Sinmed, Cablon Medical, Leiden, The Netherlands). 
Gross tumor volume (GTV) was delineated using all available clinical, iconographic and 
metabolic information. A planning target volume (PTV) around the GTV, with margins 
depending on the site irradiated (2 mm margins for bone metastases, 3 mm for nodes and 5 
mm for other sites, except for the liver where a 1 cm margin was used). Organs at risk were 
delineated, depending on the site of the GTV. 
Two radiation schedules were used. For patients treated between 2005 and May 2012, a dose 
of 50 Gy in 10 fractions of 5 Gy was prescribed to the PTV, combined with a single injection 
of a short acting (1 month depot) LHRH analogue [13]. For patients treated after this period a 
median dose of 30 Gy in 3 fractions of 10 Gy was delivered without concomitant LHRH. A 
switch from 10 fractions to 3 fractions was made for economic and logistic advantages. The 
normalized total dose of both schedules as calculated with the linear-quadratic model is 
comparable (87.5 Gy and 90 Gy for 10 x 5 Gy and 3 x 10 Gy, respectively, for an α/β ratio of 
2) [14]. Fractions were separated >40 h and <96 h. Treatment was prescribed to the periphery 
of the PTV (80% of the dose (=30 or 50 Gy), covering 90% of the PTV). The dose was 
reduced in case of violation of maximal tolerated dose of organs at risks [15]. Intensity 
modulated radiotherapy with static beams or dynamic arcs was delivered 3 times a week 
using 6–18 MV photons from a linear accelerator equipped with a multileaf collimator and 
cone-beam CT (CBCT) (Varian CLINAC, Varian, Palo Alto, CA or Elekta Synergy, Elekta, 
Crawley, UK). 
At each fraction, a CBCT was used for patients’ set-up and target verification, with correction 
of all shifts without minimal action level. Patients were repositioned in case of detection of 
rotational errors of non-spherical target volumes exceeding 3 degrees. Automatic matching 
was done using bone or soft tissue window settings for respectively bone or lymph node 
metastases. For the patient diagnosed with liver metastasis, a free breathing simulation-CT 
was fused with PET-CT and MRI. No abdominal compression or fiducials were used. In case 
of multiple (1 to 3) synchronous lesions, all lesions were treated in the same session and the 
positioning protocol was repeated per lesion. 
Evaluation of response 
The primary endpoint was ADT-free survival (ADT-FS), defined as the time interval between 
the first day of SBRT and the initiation of palliative ADT. ADT was initiated if more than 3 
metastases were detected during follow-up even when patients were still asymptomatic. The 
type of ADT was left at the discretion of the treating physician. Local progression (LP) was 
defined as tumor progression within the irradiated PTV. Each metastasis was a target lesion 
independently assessed for response with the RECIST criteria. In addition, metastases 
(particularly osseous) with a metabolic complete response on bone or PET scan were scored 
as complete response in the absence of progression on CT scan. Progression free-survival 
(PFS) was defined as the absence of new metastases and/or progression of untreated 
metastases. During treatment, patients were clinically evaluated weekly and at 1 and 3 
months thereafter. Follow-up visits with prostate specific antigen (PSA) measurement were 
scheduled 3-monthly during the first year and 6-monthly thereafter. Reassessments with bone 
scan and PET/CT imaging was performed in case of 3 rising PSA values after initial 
response, in case of PSA rise above the pre-SBRT PSA that was confirmed at least once or if 
clinically indicated to rule out local or distant metastatic progression. In case of an 
oligometastatic recurrence outside the previous SBRT field, a retreatment with SBRT was 
offered. 
Toxicity was evaluated and graded according to the National Cancer Institute (NCI) Common 
Terminology Criteria for Adverse Events (CTCAE) v3.0 [16]. Late effects were designated as 
events occurring > 3 months following treatment or as an event lasting >3 months after 
treatment. 
Statistics 
The Kaplan-Meier method was used to estimate rates of ADT-FS, LP, PFS and prostate 
cancer specific survival (PCSS). Calculations were done from the start of SBRT. Potential 
prognostic factors were examined using univariate proportional hazards regression from 
diagnosis of metastases to start of ADT. Variables exhibiting a p-value ≤ 0.15 in univariate 
analysis were entered manually in Cox proportional hazards models in a forward stepwise 
fashion. Variable retention was based on the likelihood ratio test and change in estimated 
hazard ratios for variables already present. Potential variable selection for univariate analysis 
was based on previous papers on noncastrate metastases [5,6,16]. The pattern of metastatic 
spread at time of metastasis was defined as minimal disease in case of involvement of nodes 
or axial skeleton and as extensive disease as involvement of appendicular skeleton (with or 
without axial skeleton) or viscera (lung or liver) as suggested previously [16]. Additionally, 
the total number of metastases was calculated counting all metastatic spots separately. The 
premetastatic PSA doubling time (PSA DT) was calculated by assuming first-order kinetics 
and based on all PSA measurements within 1 year (yr) prior to development of noncastrate 
metastatic disease with a minimum of three measurements, separated by a minimum of 4 
weeks. All variables were entered continuously except for risk group at PCa diagnosis: low 
(T1-T2a and Gleason ≤6 and PSA <10 ng/ml), intermediate (T2b-T2c or Gleason = 7 or PSA 
10-20 ng/ml), high (T3a or Gleason 8–10 or PSA > 20 ng/ml) and very high-risk (cT3b-T4 
N0 or any T, N1, any Gleason) [9]. Risk groups were based on the final pathological staging 
in case of surgery. All statistical analyses were performed using SPSS version 21 (SPSS, 
Chicago, IL) with p <0.05 considered significant. 
Results 
Patient characteristics 
Fifty patients were included in the current study. Table 1 summarizes patient and disease 
characteristics at time of PCa diagnosis and at time of SBRT. The majority of patients was 
treated with multimodality treatment at PCa diagnosis (Table 1). A pelvic lymph node 
dissection (PLND) was performed in 32 patients (64%), being positive in 5 patients (10%). 
During PLND, a median number of 8 nodes was removed. The median interval from PCa 
diagnosis to first metastatic event was 4.8 yr with a median PSA of 5.1 ng/ml and a PSA DT 
of 3.8 months (mo) at time of metastases (Table 1). In total 70 metastatic lesions were 
treated: lymph nodes (54%), bone (44%), and viscera (2%). Thirteen out of 24 patients with a 
pelvic recurrence had a PLND at initial treatment. The pattern of metastatic spread was 
categorized as minimal in 70% and extensive in 30% of patients according to the criteria of 
Yossepowitch et al. [17]. The different subsites of metastatic involvement are depicted in 
Table 1. The median PSA level at time of detection of metastatic disease was 5.0 ng/ml 
(range 0.2 – 45.4 ng/ml) compared to 5.1 ng/ml (0.6-116.7 ng/ml) for patients screened with 
FDG-PET-CT and choline PET-CT, respectively (p = 0.71). 
Table 1 Patient characteristics 
Characteristics All patients (n = 50) 
Age at diagnosis (yrs)  
Median (IQR) 59 (55–62) 
Follow-up from PCa diagnosis (yrs)  
Median (IQR) 7.8 (5.3-10.5) 
Primary therapy  
Radical prostatectomy alone 6 (12%) 
Radical prostatectomy with postoperative RT 22 (44%) 
Radical prostatectomy with postoperative RT + ADT 14 (28%) 
Radiotherapy + ADT 6 (12%) 
Radiotherapy alone 2 (4%) 
PSA at initial diagnosis (ng/ml)  
Mean (range) 16 (3.5-81) 
Median (IQR) 10.4 (7–16.9) 
Prognostic grouping  
Low 1 (2%) 
Intermediate 16 (32%) 
High 19 (38%) 
Very high 14 (28%) 
Interval from diagnosis to metastases (yr)  
Mean (range) 5.3 (0.2 – 15) 
Median (IQR) 4.8 (2.9 – 7.3) 
PSA level at first documented metastases (ng/ml)  
Mean (range) 10.9 (0.2 – 117) 
Median (IQR) 5.1 (2.0 – 8.6) 
PSA DT at first documented metastases (mo)  
Mean (range) 6.0 (1 – 30) 
Median (IQR) 3.8 (3.0 – 6.9) 
Number of lesions at diagnosis of metastases  
1 metastasis 37 (74%) 
2 metastases 8 (16%) 
3 metastases 6 (12%) 
Primary site of metastases  
Lymph nodes  
  Pelvic 24 (50%) 
    Obturator 1 (2%) 
    Internal iliac 6 (12%) 
    External iliac 10 (20%) 
    Presacral 2 (4%) 
    Common iliac 3 (6%) 
    Combination of nodal sites 2 (4%) 
  Extrapelvic 1 (2%) 
  Both 2 (4%) 
Bones  
  Axial 8 (16%) 
  Appendicular 11 (22%) 
  Both 3 (6%) 
Viscera  
  Liver 1 (2%) 
Treatment at time of metastases (%)  
SBRT 10 x 5 Gy + 1 mo ADT 35 (70%) 
SBRT 3 x 10 Gy 15 (30%) 
Abbreviations: yr year, mo months, IQR interquartile range. 
Patterns of progression 
Patterns of first progression following SBRT were recorded and are displayed in Figure 1. 
After a median follow-up of 2 years (interquartile range, IQR: 8 – 52 mo), 18 patients were 
disease-free and 32 patients experienced distant metastatic progression, resulting in a median 
PFS of 19 mo (95% CI: 13–25 mo) (Figure 2a). The 1-year and 2-year PFS rates were 64% 
and 35% respectively. None of the patients had a local recurrence, resulting in a 100% local 
control rate. The median PSA at recurrence was 8.5 ng/ml (IQR: 2 – 32 ng/ml) with a median 
doubling time of 2.7 mo (IQR: 1.5 – 4.7 mo). 
Figure 1 Schematic overview of relapse pattern of oligometastic prostate cancer 
recurrence following stereotactic body radiotherapy. 
Figure 2 Probability of progression-free survival (a) and androgen deprivation therapy-
free survival (b). 
For patients with initial pelvic lymph node metastases, 67% of the relapses were located in 
the pelvis or retroperitoneal nodes (Figure 3a) and 33% in the bone. For patients with initial 
bone metastases, the first site of recurrence following SBRT was located in the bone in 88% 
of the cases (Figure 3b). Initial progression was again limited to ≤3 metastases in 75% of 
recurrent patients (N = 24), of which 16 patients received a second course of SBRT and 3 
patients received a salvage pelvic lymphadenectomy. The remaining 5 oligometastatic 
patients and 8 polymetastatic patients received palliative ADT. In the former, the patients 
refused a second course of SBRT. 
Figure 3 Pattern of relapse of pelvic lymph node (a) and bone metastases (b). 
At last follow-up, 4 out of 19 patients remain progression-free following a second course of 
SBRT or salvage surgery. In 6 patients, progression was limited to ≤3 metastases and in 9 
patients it exceeded 3 metastases. Four out of 6 oligometastatic patients received a third 
course of SBRT, while the 2 other patients preferred ADT. The remaining patients received 
palliative ADT. 
One patient relapsed in the prostatic fossa following a 3rd course of SBRT and one patient 
relapsed with 3 metastatic lesions, while the other 2 remain progression-free at last follow-up. 
The patient with the local relapse received salvage radiotherapy to the prostate bed and is 
currently progression-free. The other patient received a 4th course of SBRT to the metastases 
and is currently progression-free. 
To summarize, 26 patients (52%) are progression-free at last follow-up, while 24 patients 
started with palliative ADT. This results in a median ADT-FS of 25 mo (95% confidence 
interval, CI,: 20–30 mo) (Figure 2b), with a 1-year and 2-year rate of ADT-FS of 82% and 
60% respectively. On univariate analysis, only a short PSA DT prior to SBRT was a 
significant predictor for both PFS (HR: 0.90, 95%CI: 0.82 – 0.99) and ADT-FS (HR: 0.83; 
95%CI: 0.71 – 0.97) (Table 2). The median PFS survival was 12 mo for patients with a DT ≤ 
3 mo compared to 21 mo for patients with a longer DT (p = 0.016) (Figure 4a). The median 
ADT-FS for patients with a PSA DT ≤ 3mo was 18 mo compared to 39 mo for patients with a 
longer DT (p = 0.014) (Figure 4b). No multivariate analysis was performed as none of the 
other variables in Table 2 had a p-value ≤ 0.15. 
Table 2 Univariate Cox proportional hazards model predicting androgen deprivation 
therapy-free survival and progression-free survival 
Covariate ADT-FS  PFS  
 HR (95% CI) p-value HR (95% CI) p-value 
Prognostic group at diagnosis     
  Low-Intermediate 1 0.72 1 0.41 
  High 0.99 (0.36 – 2.74)  0.78 (0.33 – 1.88) 0.58 
  Very high 1.45 (0.48 – 4.4)  1.40 (0.56 – 3.53) 0.47 
Interval from diagnosis to metastases (yr) 1 (0.99 – 1.01) 0.51 1 (0.99 – 1.01) 0.55 
PSA level at time of metastases (ng/ml) 1 (0.97 – 1.03) 0.96 1 (0.98 – 1.03) 0.67 
PSA DT at time of metastases (mo) 0.83 (0.71 – 0.97) 0.02 0.90 (0.82 – 0.99) 0.04 
Number of lesions at diagnosis of metastases 1.11 (0.56 – 2.22) 0.75 1.02 (0.53 – 1.94) 0.96 
Pattern of metastatic spread     
  Minimal 1 0.37 1 0.27 
  Extensive 1.48 (0.63 – 3.49)  1.53 (0.72 – 3.2)  
Location of metastasis *     
  Node 1 0.10 1 0.25 
  Bone 2.02 (0.87 – 4.72)  1.54 (0.74 – 3.22)  
Abbreviation: HR hazard ratio, CI confidence interval, yr year, mo month, ADT-FS androgen deprivation therapy-free 
survival, PFS progression-free survival. 
*
 The patient with liver metastasis was excluded from the analysis of this variable. P-values in bold represent significant 
values <0.05. 
Figure 4 Probability of progression-free survival (a) and androgen deprivation therapy-
free survival (b) stratified according to PSA doubling time ≤ 3mo compared to > 3 mo. 
Five patients died of prostate cancer, resulting in a 2-year and 5-year PCSS of 96% and 90% 
respectively. There were no non-prostate cancer related deaths. 
Toxicity 
Ten patients (20%) developed toxicity following treatment, which was classified as grade I in 
7 and grade II in 3 patients. In case of bone metastasis irradiation, 3 patients reported mild 
grade I bone pain and 1 patient was diagnosed with an asymptomatic fracture of the ilium on 
follow-up PET-CT without the necessity of treatment (grade I). In case of SBRT for nodal 
metastases, 1 patient experienced grade I fatigue and 4 patients experienced diarrhoea (grade 
I: n = 2 and grade II: n = 2). One patient experienced a worsening of his post-radical 
prostatectomy urinary incontinence (grade II) six months after SBRT of a pelvic node. 
Discussion 
Metastatic prostate cancer is clearly a heterogeneous disease, with the number of metastases 
at recurrence being recognized as an important prognostic factor [5,6]. However, two major 
difficulties have complicated assessment of the benefit of radical treatment for 
oligometastases. 
First, the identification of patients with truly oligometastatic disease is inherently 
challenging. When using bone scintigraphy as a single re-staging modality, the proportion of 
patients diagnosed with ≤5 lesions is only 41% [18]. With the addition of computed 
tomography (CT), 73% of patients is diagnosed with ≤3 metastases with a median PSA of 25 
ng/ml [5]. With the introduction of more sensitive and specific imaging modalities such as 
PET-CT and MRI [10,19], oligometastatic disease is detected even earlier at median PSA 
levels around 7 ng/ml or lower [6,10]. Consequently, both the time between a PSA rise and 
the detection of metastatic disease is reducing as well as the number of metastases detected 
[6]. In the current study, the majority of patients were staged with FDG-PET-CT and only a 
minority with choline PET-CT. Thus, a proportion of patients might have been understaged 
[10], potentially leading to underestimation of the effect of the treatment. However, the 
median PSA level at time of detection of metastatic disease was comparable between both 
FDG and choline in our population. A recent dual-tracer study concluded that although 
choline appears to be more sensitive than 18 F-FDG for the detection of disease in PSA 
relapse, 18 F-FDG correlated better with more aggressive disease [20]. Unfortunately, both 
FDG and choline PET-CT, still underestimate the extent of disease [21]. This is also clearly 
reflected in our patients treated with SBRT for pelvic lymph nodes, with two out of three 
patients relapsing in the nodes again. As an alternative to a lesion based approach such as 
SBRT, the inclusion of an elective nodal volume in the radiotherapy field might reduce these 
type of relapses. Other groups have started implementing this type of treatment with 
promising results, however details on the pattern of relapse are lacking [22-24]. Newer 
tracers, such as (68)Ga-labelled prostate-specific membrane antigen (PSMA), look very 
promising with a higher yield of lesions with an improved tumor to background ratio [25], 
but need further validation. Although currently not commercially available, ultrasmall 
superparamagnetic particles of iron oxide MRI remains one of the most promising imaging 
modalities for detecting of metastases of normal-sized lymph nodes in PCa [26]. Further 
improvements in imaging will enable better patient selection for lesion-based therapies. 
The second hurdle for delivering radical treatment to metastases by means of radiation was 
the need for extended fractionation for the delivery of ablative doses to the lesion while 
avoiding normal tissue toxicity. The development of new radiotherapy planning and 
treatment technologies have enabled the safe delivery of an equivalent or higher biological 
effective doses in a reduced number of treatment sessions as compared to a standard 5–7 
week course. Nevertheless, SBRT has only been recently implemented for oligometastatic 
PCa as is demonstrated by the limited number of publications [21,23,27-29]. In a recent 
systematic review including a mixture of primary solid tumours, it was concluded that SBRT 
for oligometastatic disease is accompanied with low toxicity and excellent local control [8]. 
About 20% of patients remain progression free at 2–3 years after SBRT [8]. Our study is in 
agreement with these findings, showing a 100% local control without grade III toxicity. This 
supports the 2 fractionation schedules used in our study delivering a biological dose of 
around 90 Gy. The 2-year progression-free survival of 35% is in line with that of other solid 
tumors [8]. However, it is on the lower end compared to the other reported PCa series 
[23,28,29]. This might be partially explained by the fact that most series used concomitant 
ADT for more than 6 months [23,28,29]. It should also be noted that the number of patients 
treated is lower in other studies and that most of them only included patients with a single 
metastasis, which might influence outcome [5,6]. 
We identified PSA DT as the only variable influencing clinical progression and ADT-FS 
[5,6]. Initial patient stratification based on PSA DT might help us select the ideal candidates 
for SBRT. We observed that the pattern of progression after SBRT is most often 
oligometastatic. Consequently, these patients were offered repeated SBRT to postpone 
progression to polymetastatic disease requiring systemic treatment. In 50% of the patients we 
were able to postpone palliative androgen deprivation therapy by at least 2 years. 
Additionally, this surrogate endpoint describes the proportion of patients who no longer can 
be ‘salvaged’ with repeat SBRT, as the majority of patients (17 of 24 cases) were started on 
ADT because of polymetastatic progression. Although promising, the true benefit of SBRT 
can only be assessed through randomization. A randomized phase II trial comparing active 
surveillance with eradication of oligometastatic disease by means of SBRT or surgery is 
halfway recruiting (http://clinicaltrials.gov: NCT01558427). In the meanwhile, SBRT for 
oligometastatic PCa should be considered investigational. 
Despite being the largest series reporting on the outcome of SBRT for oligometastatic PCa, 
several limitations should be addressed. The median follow-up is too short to reliably report 
endpoints such as PCSS. The rationale of the addition of single injection of a 1-month 
preparation of an LHRH-analogue with the initiation of SBRT was to increase 
radiosensitivity. However, this makes the interpretation of biochemical response increasingly 
difficult, as all patients had an initial PSA decline. Consequently, we decided to stop the 
combination therapy from May 2012 onwards to get a clear view on the true benefit of SBRT 
in this setting. However, the influence ADT on PFS and ADT-FS is probably limited as the 
duration of testosterone suppression by a 1-month depot of an LHRH- analogue is only 
between 2 and 4 months depending on the definition of testosterone recovery [30]. It might 
be hypothesized from the excellent toxicity profile of SBRT that the quality of life in these 
patients might be superior compared to patients receiving immediate ADT. Unfortunately, 
these data were not registered in our study, but are currently being prospectively collected. 
Conclusions 
Repeated SBRT for oligometastatic prostate cancer postpones palliative androgen deprivation 
therapy with 2 years without grade III toxicity. 
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